Esho Pharma Limited
Unaudited Financial Statements
For the year ended 31 March 2023
Pages for Filing with Registrar
Company Registration No. 12408932 (England and Wales)
Esho Pharma Limited
Contents
Page
Balance sheet
1
Notes to the financial statements
2 - 4
Esho Pharma Limited
Balance Sheet
As at 31 March 2023
Page 1
2023
2022
Notes
£
£
£
£
Current assets
Stock
154,312
149,696
Debtors
3
34,327
44,996
Cash at bank and in hand
4,220
77,522
192,859
272,214
Creditors: amounts falling due within one year
4
(442,122)
(272,069)
Net current (liabilities)/assets
(249,263)
145
Capital and reserves
Called up share capital
5
1
1
Profit and loss reserves
(249,264)
144
Total equity
(249,263)
145

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 3 February 2025
Dr O O Esho
Director
Company Registration No. 12408932
Esho Pharma Limited
Notes to the Financial Statements
For the year ended 31 March 2023
Page 2
1
Accounting policies
Company information

Esho Pharma Limited is a private company limited by shares incorporated in England and Wales. The registered office is Charlotte Building, 17 Gresse Street, London, W1T 1QL.

1.1
Accounting convention

These financial statements have been prepared in accordance with Section 1A of FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

The company suffered a net loss in the year of £true249,407 (2022: £28,071 profit after tax) and at the balance sheet date had net liabilities of £249,263 (2022: £145 net assets).

 

At the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future and will continue to be financially supported by the group. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

1.4
Stock

Stock are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stock to their present location and condition.

 

Stock held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stock over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.5
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand and deposits held at call with banks.

1.6
Financial instruments

The company only has basic financial instruments measured at amortised cost.

Esho Pharma Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2023
1
Accounting policies
(Continued)
Page 3
1.7
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

1.8
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
Total
-
0
-
0
3
Debtors
2023
2022
Amounts falling due within one year:
£
£
Trade debtors
14,186
37,765
Amounts owed by group undertakings
-
0
6,179
Other debtors
19,719
612
Prepayments and accrued income
422
440
34,327
44,996
Esho Pharma Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2023
Page 4
4
Creditors: amounts falling due within one year
2023
2022
£
£
Trade creditors
60,254
62,635
Amounts owed to group undertakings
374,271
57,732
Corporation tax
32
1,056
Other creditors
-
107,764
Accruals and deferred income
7,565
42,882
442,122
272,069
5
Called up share capital
2023
2022
2023
2022
Ordinary share capital
Number
Number
£
£
Issued and not fully paid
1 Ordinary share of £1 each
1
1
1
1

 

6
Related party transactions

Included in creditors a balance of £362,037 (2022: £57,732) due to Esho Medical Limited, a company under common control.

 

Included in creditors a balance of £12,234 (2022: £6,179 due to Esho MD Retail Limited included in other debtors) due from Esho MD Retail Limited, a company under common control.

 

At the balance sheet date £nil (2022: £107,764) is due to the director.

7
Parent company

The parent company is Esho Holdings Limited by virtue of its 100% shareholding in the company.

The ultimate controlling party is Dr O O Esho, the director of the company, by virtue of his 100% shareholding in the immediate parent company; Esho Holdings Limited.

2023-03-312022-04-01falsefalsefalse03 February 2025CCH SoftwareCCH Accounts Production 2024.301No description of principal activityDr O O Esho12408932124089322022-04-012023-03-31124089322023-03-31124089322022-03-3112408932core:CurrentFinancialInstrumentscore:WithinOneYear2023-03-3112408932core:CurrentFinancialInstrumentscore:WithinOneYear2022-03-3112408932core:ShareCapital2023-03-3112408932core:ShareCapital2022-03-3112408932core:RetainedEarningsAccumulatedLosses2023-03-3112408932core:RetainedEarningsAccumulatedLosses2022-03-3112408932bus:Director12022-04-012023-03-31124089322021-04-012022-03-3112408932core:CurrentFinancialInstruments2023-03-3112408932core:CurrentFinancialInstruments2022-03-3112408932bus:PrivateLimitedCompanyLtd2022-04-012023-03-3112408932bus:FRS1022022-04-012023-03-3112408932bus:AuditExemptWithAccountantsReport2022-04-012023-03-3112408932bus:SmallCompaniesRegimeForAccounts2022-04-012023-03-3112408932bus:FullAccounts2022-04-012023-03-31xbrli:purexbrli:sharesiso4217:GBP